﻿<?xml version="1.0" encoding="utf-8"?>
<!-- generator="Joomla! 1.5 - Open Source Content Management" -->
<?xml-stylesheet href="/indeks/media/system/css/modal.css" type="text/css"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Adnan Mustafa</title>
		<description>Pharmaks - most visited Albanian website in internet for pharmacy and medicine.</description>
		<link></link>
		<lastBuildDate>Thu, 19 Jul 2012 02:29:07 +0000</lastBuildDate>
		<generator>Joomla! 1.5 - Open Source Content Management</generator>
		<language>sq-al</language>
		<item>
			<title>Pharmaks Agency</title>
			<link>/indeks/index.php/component/k2/item/206-pharmaks-agency</link>
			<guid>/indeks/index.php/component/k2/item/206-pharmaks-agency</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><!--  /* Font Definitions */  @font-face 	{font-family:Wingdings; 	panose-1:5 0 0 0 0 0 0 0 0 0; 	mso-font-charset:2; 	mso-generic-font-family:auto; 	mso-font-pitch:variable; 	mso-font-signature:0 268435456 0 0 -2147483648 0;} @font-face 	{font-family:"HelveticaNeueLT Pro 75 Bd"; 	panose-1:0 0 0 0 0 0 0 0 0 0; 	mso-font-charset:0; 	mso-generic-font-family:swiss; 	mso-font-format:other; 	mso-font-pitch:variable; 	mso-font-signature:135 0 0 0 155 0;}  /* Style Definitions */  p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0mm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} @page Section1 	{size:612.0pt 792.0pt; 	margin:72.0pt 90.0pt 72.0pt 90.0pt; 	mso-header-margin:35.4pt; 	mso-footer-margin:35.4pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */  @list l0 	{mso-list-id:1052385111; 	mso-list-type:hybrid; 	mso-list-template-ids:-59857098 -1548738896 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;} @list l0:level1 	{mso-level-number-format:bullet; 	mso-level-text:&#61607;; 	mso-level-tab-stop:18.0pt; 	mso-level-number-position:left; 	margin-left:18.0pt; 	text-indent:-18.0pt; 	font-family:Wingdings;} ol 	{margin-bottom:0mm;} ul 	{margin-bottom:0mm;} --><!--  /* Font Definitions */  @font-face 	{font-family:Wingdings; 	panose-1:5 0 0 0 0 0 0 0 0 0; 	mso-font-charset:2; 	mso-generic-font-family:auto; 	mso-font-pitch:variable; 	mso-font-signature:0 268435456 0 0 -2147483648 0;} @font-face 	{font-family:"HelveticaNeueLT Pro 75 Bd"; 	panose-1:0 0 0 0 0 0 0 0 0 0; 	mso-font-charset:0; 	mso-generic-font-family:swiss; 	mso-font-format:other; 	mso-font-pitch:variable; 	mso-font-signature:135 0 0 0 155 0;}  /* Style Definitions */  p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0mm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} @page Section1 	{size:612.0pt 792.0pt; 	margin:72.0pt 90.0pt 72.0pt 90.0pt; 	mso-header-margin:35.4pt; 	mso-footer-margin:35.4pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */  @list l0 	{mso-list-id:1052385111; 	mso-list-type:hybrid; 	mso-list-template-ids:-59857098 -1548738896 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;} @list l0:level1 	{mso-level-number-format:bullet; 	mso-level-text:&#61607;; 	mso-level-tab-stop:18.0pt; 	mso-level-number-position:left; 	margin-left:18.0pt; 	text-indent:-18.0pt; 	font-family:Wingdings;} ol 	{margin-bottom:0mm;} ul 	{margin-bottom:0mm;} --><p class="MsoNormal"><!--  /* Font Definitions */  @font-face 	{font-family:Wingdings; 	panose-1:5 0 0 0 0 0 0 0 0 0; 	mso-font-charset:2; 	mso-generic-font-family:auto; 	mso-font-pitch:variable; 	mso-font-signature:0 268435456 0 0 -2147483648 0;}  /* Style Definitions */  p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0mm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} @page Section1 	{size:612.0pt 792.0pt; 	margin:72.0pt 90.0pt 72.0pt 90.0pt; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */  @list l0 	{mso-list-id:1052385111; 	mso-list-type:hybrid; 	mso-list-template-ids:-59857098 -1548738896 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;} @list l0:level1 	{mso-level-number-format:bullet; 	mso-level-text:&#61607;; 	mso-level-tab-stop:18.0pt; 	mso-level-number-position:left; 	margin-left:18.0pt; 	text-indent:-18.0pt; 	font-family:Wingdings;} ol 	{margin-bottom:0mm;} ul 	{margin-bottom:0mm;} --></p><p style="margin-top: 6pt" class="MsoNormal"><img src="/indeks/templates/rhuk_solarflare_ii/images/powered_by.gif" alt="Pharmaks Agency" title="Pharmaks Agency" width="170" height="79" /> </p><p style="margin-top: 6pt" class="MsoNormal"><strong><span style="font-family: Arial; color: #ff6600; font-size: 10pt">Small Company &ndash; Smart Solutions</span></strong></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">PHARMAKS is Agency for publication, marketing, counselling and regulatory affairs for Kosova medicine, medical device and food supplement market. PHARMAKS is dealing in Marketing Authorization Application according to national and EU regulatory requirements and procedures (medicinal products) or registrations (herbal medicinal products and food supplements) and notification or certification processes (medical devices).</span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">We are also producing Summary Product Characteristics and Patient Information Leaflets of medicines according to national and EU rules.</span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">PHARMAKS professional team includes highly experienced pharmacists, physicians and health related professionals.</span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">PHARMAKS is leading agency in Kosova for professional translation in the fields of pharmaceuticals and medicine.&nbsp;</span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">More than 20 world known pharmaceutical companies were our clients: </span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Sanofi-Aventis, Sanofi-Pasteur, Hoffmann La Roche, Boehringer Ingelheim, Bayer, AstraZeneca, Abbot Laboratories, Abbot, Dr. Falk Pharma, Johnson &amp; Johnson, Jansen-Cilag, Nycomed, Engelhard, Natural Wealth, Bosnalijek, Jadran Galenski Laboratorij, Hemofarm, Novit Pharm, Actavis, Merck KGaA, Merck Serono, Berlin Chemie - Menarini Group, Solvay Pharma, Nivea, etc.</span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">PHARMAKS was first to translate from English into Albanian Glossary of pharmaceutical forms of EDQM.</span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Reliability, accuracy, trustfulness and professionalism are our added values in relations with our clients.</span></p><p style="margin-top: 6pt" class="MsoNormal"><strong><span style="font-family: Arial; color: #003366; font-size: 10pt">Portfolio of PHARMAKS:</span></strong></p><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Marketing Authorization Applications and procedures</span></li></ul><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Pharmacovigilance</span></li></ul><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Professional translations (pharmaceutical, medical, legal, etc)</span></li></ul><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Publishing</span></li></ul><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Pharmaceutical and medical regulatory affairs</span></li></ul><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Pharmaceutical and medical marketing</span></li></ul><ul><li><span style="font-family: Arial; color: #003366; font-size: 10pt">Continual health professional development</span></li></ul><p style="margin-top: 6pt" class="MsoNormal">&nbsp;</p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: maroon; font-size: 10pt">PharmINDEX 2009</span><span style="font-family: Arial; font-size: 10pt"> <span style="color: #003366">&ndash;&nbsp;was the bestselling pharmaceutical and medicinal book in Republic of Kosova in 2009.</span></span></p><p style="margin-top: 6pt" class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Our website </span><span style="font-family: Arial; color: maroon; font-size: 10pt"><a href="/"><span style="color: maroon">www.pharmaks.com</span></a></span><span style="font-family: Arial; color: #003366; font-size: 10pt"> is most visited portal for pharmacy and medicine in Albanian language.</span></p><p style="margin-top: 6pt" class="MsoNormal"><strong><em><span style="font-family: Arial; color: #ff6600; font-size: 10pt">PHARMAKS is agency you can ever trust.</span></em></strong></p><p class="MsoNormal">&nbsp;</p><p class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Address:</span></p><p class="MsoNormal"><strong><span style="font-family: Arial; color: #003366; font-size: 10pt">Ulpiana D9/3/2</span></strong></p><p class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Prishtin&euml;</span></p><p class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Republic of Kosova</span></p><p class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">Phone/fax: +381 38 55 11 47 </span></p><p class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">mobile phone: +377 44 166 590, +377 44 138 254, +386 49 166 590, + 386 49 138 254</span></p><p class="MsoNormal"><span style="font-family: Arial; color: #003366; font-size: 10pt">email: <a href="mailto:info@pharmaks.com"><span style="color: #003366">info@pharmaks.com</span></a>, <a href="mailto:a.mustafa@pharmaks.com"><span style="color: #003366">a.mustafa@pharmaks.com</span></a>, <a href="mailto:l.sharapolli@pharmaks.com"><span style="color: #003366">l.sharapolli@pharmaks.com</span></a> </span></p><span style="font-family: Arial; color: #003366; font-size: 10pt">website: <a href="/"><span style="color: #003366">www.pharmaks.org</span></a></span>&nbsp; <p>&nbsp;</p></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Uncategorized</category>
			<pubDate>Thu, 19 Aug 2004 20:11:07 +0000</pubDate>
		</item>
		<item>
			<title>Avastin-FDA revokim për kancer gjini</title>
			<link>/indeks/index.php/component/k2/item/203-avastin-fda-revokim-për-kancer-gjini</link>
			<guid>/indeks/index.php/component/k2/item/203-avastin-fda-revokim-për-kancer-gjini</guid>
			<description><![CDATA[<div class="K2FeedIntroText">Paralajm&euml;rim sigurie: Komisioneri i FDA, Margaret A. Hamburg, MD, ka revokuar aprovimin e Avastin&#39;&euml;s (bevacizumab; Genentech) p&euml;r tretman t&euml; kancerit t&euml; gjinit pas konkludimit q&euml; bari nuk ka qen&euml; i sigurt dhe efektiv p&euml;r at&euml; p&euml;rdorim. <a href="http://www.empr.com/safety-alert-fda-revokes-approval-of-avastin-for-use-in-breast-cancer/article/217105/">Shikoni k&euml;tu</a></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Flash lajme</category>
			<pubDate>Tue, 22 Nov 2011 21:29:16 +0000</pubDate>
		</item>
		<item>
			<title>Ondansetron-rrezik i mundshëm për QT prolongim</title>
			<link>/indeks/index.php/component/k2/item/188-ondansetron-rrezik-i-mundshëm-për-qt-prolongim</link>
			<guid>/indeks/index.php/component/k2/item/188-ondansetron-rrezik-i-mundshëm-për-qt-prolongim</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10px; font-style: normal; font-variant: normal; font-weight: normal" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font style="font-family: Arial, Helvetica, sans-serif; font-size: 10px" color="#000000"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/zofran_4mg_10s.gif" width="120" height="174" hspace="6" alt="Zofran" title="Zofran" border="0" /></div> <span style="font-family: Arial; font-size: 10pt">FDA ka njoftuar profesionist&euml;t sh&euml;ndet&euml;sor p&euml;r rishikimin e siguris&euml; q&euml; &euml;sht&euml; duke vazhduar p&euml;r Zofran (ondansetron; GlaxSmithKline) p&euml;r shkak t&euml; rrezikut t&euml; shtuar p&euml;r zhvillimin e prolongimit QT, i cili mund t&euml; &ccedil;oj&euml; deri te ritmi i zemr&euml;s abnormal dhe potencialisht fatal (p&euml;rfshir&euml; edhe Torsades de pointes).</span></font></span><font face="Times New Roman" size="3" color="#000000">&nbsp; </font></p></div><div class="K2FeedFullText"><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Pacient&euml;t n&euml; rrezik t&euml; posa&ccedil;&euml;m p&euml;r zhvillim t&euml; torsades de pointes p&euml;rfshijn&euml; ata me s&euml;mundje t&euml; zemr&euml;s, si&ccedil; &euml;sht&euml; sindroma kongjenitale e QT prolongimit, ata t&euml; cil&euml;t jan&euml; t&euml; predispozuar p&euml;r nivele t&euml; ulta t&euml; kaliumit dhe magneziumit n&euml; gjak dhe ata q&euml; marrin barna tjera q&euml; &ccedil;ojn&euml; deri te QT prolongimi. </font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Nga GlaxoSmithKline &euml;sht&euml; k&euml;rkuar q&euml; t&euml; nd&euml;rmarrin studim QT t&euml; t&euml;r&euml;sish&euml;m p&euml;r t&euml; vler&euml;suar potencialin e Zofran&#39;it p&euml;r t&euml; prolonguar QT intervalin. </font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Rezultatet nga ky studim priten t&euml; jen&euml; n&euml; dispozicion n&euml; ver&euml; t&euml; 2012.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Zofran &euml;sht&euml; i indikuar p&euml;r t&euml; prevenuar p&euml;shtirosjen dhe vjelljen e shkaktuar nga kimioterapia e kancerit, terapia e rrezatimit dhe operacioni kirurgjik.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">P&euml;r ma shum&euml; informacione vizitoni: www.fda.gov/Drugs/DrugSafety/ucm271913.htm</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">http://www.empr.com/zofran/nausea/drug/5144/</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">http://www.empr.com/glaxosmithkline-pharmaceuticals/manufacturer/11397/</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">http://www.empr.com/zofran/nausea/drug/5144/</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">http://www.empr.com/zofran/nausea/drug/5144/</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><span style="font-family: Arial; font-size: 10pt"><font color="#000000">http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Mon, 19 Sep 2011 04:15:01 +0000</pubDate>
		</item>
		<item>
			<title>Epoetinë alfa-modifikim dozimi</title>
			<link>/indeks/index.php/component/k2/item/187-epoetinë-alfa-modifikim-dozimi</link>
			<guid>/indeks/index.php/component/k2/item/187-epoetinë-alfa-modifikim-dozimi</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/meds/epoetin.gif" width="120" height="118" hspace="6" alt="Epoetin" title="Epoetin" border="0" /><div class="mosimage_caption">Epoetin</div></div> <!--[if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal</w:View>   <w:Zoom>0</w:Zoom>   <w:PunctuationKerning/>   <w:ValidateAgainstSchemas/>   <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false</w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>   <w:Compatibility>    <w:BreakWrappedTables/>    <w:SnapToGridInCell/>    <w:WrapTextWithPunct/>    <w:UseAsianBreakRules/>    <w:DontGrowAutofit/>   </w:Compatibility>   <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml>  <w:LatentStyles DefLockedState="false" LatentStyleCount="156">  </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style>  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} </style> <![endif]-->  <p class="MsoNormal"><strong><span style="font-size: 10pt; font-family: Arial">Barnat p&euml;r stimulimin e eritropoez&euml;s (BSE) n&euml; s&euml;mundjet kronike t&euml; veshkave:</span></strong><strong><span style="font-size: 10pt; font-family: Arial"> </span></strong><strong><span style="font-size: 10pt; font-family: Arial">Komunikat&euml; p&euml;r sigurin&euml; e barnave - rekomandime p&euml;r dozim t&euml; modifikuar</span></strong></p>    <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Epoetin&euml; alfa (n&euml; treg si Epogen dhe Procrit) dhe darbepoetin&euml; alfa (n&euml; treg si Aranesp)</span></p>    <p class="MsoNormal"><strong><span style="font-size: 10pt; font-family: Arial">AUDIENCA</span></strong><span style="font-size: 10pt; font-family: Arial">:</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Nefrologji, onkologji</span></p>    <strong><span style="font-size: 10pt; font-family: Arial">KOMUNIKATA</span></strong><span style="font-size: 10pt; font-family: Arial">:</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">FDA ka njoftuar profesionist&euml;t sh&euml;ndet&euml;sor q&euml; rekomandimet e reja t&euml; modifikuara p&euml;r dozim ma konservativ t&euml; barnave p&euml;r stimulimin e eritropoez&euml;s (BSE) n&euml; pacient&euml;t me s&euml;mundje kronike t&euml; veshkave (SKVe) &euml;sht&euml; aprovuar p&euml;r t&euml; p&euml;rmir&euml;suar p&euml;rdorimin ma t&euml; sigurt t&euml; k&euml;tyre barnave.</span></div><div class="K2FeedFullText"><!--[if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal</w:View>   <w:Zoom>0</w:Zoom>   <w:PunctuationKerning/>   <w:ValidateAgainstSchemas/>   <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false</w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>   <w:Compatibility>    <w:BreakWrappedTables/>    <w:SnapToGridInCell/>    <w:WrapTextWithPunct/>    <w:UseAsianBreakRules/>    <w:DontGrowAutofit/>   </w:Compatibility>   <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml>  <w:LatentStyles DefLockedState="false" LatentStyleCount="156">  </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style>  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} </style> <![endif]-->  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">FDA ka b&euml;r&euml; k&euml;to rekomandime p&euml;r shkak se t&euml; dh&euml;nat tregojn&euml; rritje t&euml; rrezikut nga ngjarjet kardiovaskulare me BSE n&euml; k&euml;t&euml; populacion t&euml; pacient&euml;ve.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Rekomandimet e dozimit t&euml; ri jan&euml; bazuar n&euml; trial&euml;t klinik q&euml; tregojn&euml; se p&euml;rdorimi i BSE p&euml;r t&euml; arritur cak t&euml; nivelit t&euml; hemoglobin&euml;s ma t&euml; madh se 11 g/L n&euml; pacient&euml;t me SKVe, nuk &euml;sht&euml; me leverdi t&euml; shtuar sesa caqet e niveleve ma t&euml; ulta, dhe rrit rrezikun nga p&euml;rjetimi i ngjarjeve serioze t&euml; p&euml;rkund&euml;rta kardiovaskulare, si&ccedil; jan&euml; sulmi n&euml; zem&euml;r ose n&euml; tru.</span></p>  <p class="MsoNormal"><strong><span style="font-size: 10pt; font-family: Arial">SFONDI</span></strong><span style="font-size: 10pt; font-family: Arial">:</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">BSE trajton disa tipe t&euml; anemis&euml; duke stimuluar palc&euml;n ashtrore t&euml; prodhoj&euml; qeliza t&euml; kuqe t&euml; gjakut dhe duke zvog&euml;luar nevoj&euml;n p&euml;r transfuzione gjaku.</span></p>  <p class="MsoNormal"><strong><span style="font-size: 10pt; font-family: Arial">REKOMANDIM</span></strong><span style="font-size: 10pt; font-family: Arial">:</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Profesionist&euml;t sh&euml;ndet&euml;sor duhet t&euml; masin leverdit&euml; e mundshme t&euml; p&euml;rdorimit t&euml; BSE p&euml;r t&euml; zvog&euml;luar nevoj&euml;n p&euml;r transfuzion t&euml; qelizave n&euml; pacient&euml;t me SKVe kundrejt rrezikut t&euml; shtuar p&euml;r ngjarje serioze kardiovaskulare, dhe duhet t&euml; informojn&euml; pacient&euml;t e tyre lidhur me kuptimin aktual t&euml; rrezikut dhe t&euml; leverdis&euml; potenciale.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Terapia duhet t&euml; individualizohet te pacient&euml;t dhe duhet t&euml; jepet doza ma e ult&euml; e mundshme e BSE p&euml;r t&euml; reduktuar nevoj&euml;n p&euml;r transfuzione.</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">&nbsp;</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Burimi:</span><span style="font-size: 10pt; font-family: Arial"> <span>FDA Medwatch</span></span></p>  <span style="font-size: 10pt; font-family: Arial"><a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm260641.htm">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm260641.htm</a></span></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Tue, 12 Jul 2011 23:54:03 +0000</pubDate>
		</item>
		<item>
			<title>Këshilla për rrezitje në diell</title>
			<link>/indeks/index.php/component/k2/item/186-këshilla-për-rrezitje-në-diell</link>
			<guid>/indeks/index.php/component/k2/item/186-këshilla-për-rrezitje-në-diell</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/people/sunscreen.jpg" width="180" height="120" hspace="6" alt="Rrezitja" title="Rrezitja" border="0" /></div> <font face="Times New Roman" size="3" color="#000000">  </font><div style="border-width: medium medium 1pt; border-style: none none solid; border-color: currentColor currentColor #4f81bd; padding: 0cm 0cm 4pt; margin-right: 46.8pt; margin-left: 0cm"><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 10pt 0cm 14pt; text-align: justify" class="IntenseQuote"><span style="font-family: Calibri; font-size: 10pt"><font color="#4f81bd"><font face="Times New Roman" size="3" color="#000000">  </font><span style="color: #33cccc; font-family: Calibri; font-size: 10pt"><strong><em>Udh&euml;zues p&euml;r rrezitje pa rrezikuar l&euml;kur&euml;n tuaj</em></strong></span></font></span></p><font color="#4f81bd"><p style="margin: 10pt 0cm 14pt; text-align: justify" class="IntenseQuote"><font face="Times New Roman" size="3" color="#000000">  </font><span style="color: #33cccc; font-family: Calibri; font-size: 10pt"><strong><em>Udh&euml;zimet n&euml; vijim japin informacione themelore p&euml;r mbrojtje nga rrezitja n&euml; diell</em></strong></span></p><p style="margin: 10pt 0cm 14pt; text-align: justify" class="IntenseQuote"><font face="Times New Roman" size="3" color="#000000">  </font><span style="color: #33cccc; font-family: Calibri; font-size: 10pt"><strong><em>&Ccedil;ka &euml;sht&euml; sakt&euml;sisht nxirja (marrja e ngjyr&euml;s)?</em></strong></span></p><p style="margin: 10pt 0cm 14pt; text-align: justify" class="IntenseQuote"><font face="Times New Roman" size="3" color="#000000">  </font><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Kur l&euml;kura juaj merr ngjyr&euml;, ajo n&euml; fakt mbron vetveten nga d&euml;mtimet e rrezeve ultraviolete (UV) t&euml; diellit, duke shkaktuar prodhimin e nj&euml; substance t&euml; quajtur melanin&euml;.</font></span></p></font><p style="margin: 10pt 0cm 14pt; text-align: justify" class="IntenseQuote"><font color="#000000"><span style="font-family: Calibri; font-size: 10pt"> A ekziston nxirje q&euml; mund t&euml; thuhet q&euml; &euml;sht&euml; e sigurt?</span></font></p></div></div><div class="K2FeedFullText"><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Jo. Ekspozimi i &ccedil;doditsh&euml;m n&euml; diell gjat&euml; shum&euml; viteve vendos l&euml;kur&euml;n tuaj n&euml; rrezik p&euml;r shenja t&euml; plakjes s&euml; parakohshme (psh. rrudha t&euml; vogla, l&euml;kur&euml; e vrazhd&euml;t dhe njolla boj&euml;kafe). Rezultatet e k&euml;tij d&euml;mtimi afatgjat&euml; mund t&euml; mos jen&euml; t&euml; dukshme me vite t&euml; t&euml;ra. Ekspozimet e p&euml;rs&euml;ritura n&euml; komponentet e drit&euml;s UV t&euml; rrezeve t&euml; diellit mund t&euml; &ccedil;ojn&euml; n&euml; kancer l&euml;kure. Ju mund t&euml; redukoni rrezikun duke u ekspozuar minimalisht n&euml; diell.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">&Ccedil;ka jan&euml; UVA dhe UVB dhe &ccedil;far&euml; &euml;sht&euml; signifikanca e tyre?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Jan&euml; dy tipe t&euml; rrezeve brenda drit&euml;s s&euml; diellit t&euml; cilat arrijn&euml; tok&euml;n: Drita UVA dep&euml;rton madje edhe shtresat e poshtme te l&euml;kur&euml;s dhe mendohet q&euml; shkaktojn&euml; plakjen e parakohshme dhe rrudhosjen, sikurse edhe alergjit&euml; e l&euml;kur&euml;s dhe pu&ccedil;rrat. Rrezet UVB kan&euml; efektin e tyre n&euml; sip&euml;rfaqen e l&euml;kur&euml;s dhe jan&euml; p&euml;rgjegj&euml;se p&euml;r djegie dielli. Tej-ekspozimi n&euml; secilin tip t&euml; radiacionit UV mund t&euml; &ccedil;oj&euml; te kanceri i l&euml;kur&euml;s.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">A mundet rrezitja n&euml; diell t&euml; jet&euml; me t&euml; v&euml;rtet&euml; e rrezikshme p&euml;r sh&euml;ndetin tim?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Ekspozimi i tejzgjatur ndaj diellit mund t&euml; shkaktoj&euml; kancer l&euml;kure dhe forma serioze e saj e quajtur melanoma malinje, mund t&euml; jet&euml; fatale. Melanoma malinje rritet nga lyethi ekzistues, dhe i cili mund t&euml; shkoj&euml; p&euml;rmes nj&euml; numri t&euml; nd&euml;rrimeve t&euml; ndryshme.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Nganj&euml;her&euml;, ajo mund t&euml; rritet n&euml; l&euml;kur&euml;n n&euml; t&euml; cil&euml;n nuk ka pasur m&euml; par&euml; lytha. N&euml;se v&euml;reni ndonj&euml;rin prej k&euml;tyre simptomeve, ju duhet t&euml; shkoni te mjeku juaj p&euml;r kontroll t&euml; menj&euml;hersh&euml;m.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Lyethi b&euml;het m&euml; i madh;</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Ndryshon ngjyr&euml;n apo form&euml;n</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Rrjedh gjak;</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Zhvillohet duke u rritur dhe marr&euml; form&euml; ose kontura t&euml; pazakonshme;</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Fillon t&euml; kruhet.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Format tjera t&euml; kancerit t&euml; l&euml;kur&euml;s t&euml; cilat mund t&euml; shkaktohen nga ekspozimi n&euml; diell jan&euml;:</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Karcinoma e qelizave bazale, e njohur me em&euml;r m&euml; t&euml; njohur si &ldquo;ulcera e rodent&euml;ve (brejt&euml;sve)&rdquo;. Mbi 90% t&euml; k&euml;tij tipi shfaqen n&euml; fytyr&euml; ose qaf&euml;, por ato mund t&euml; rriten n&euml; cilindo pjes&euml; t&euml; trupit. Ajo fillon si nj&euml; pu&ccedil;&euml;rr e vog&euml;l e rrafsh&euml;t dhe rritet ngadal&euml;, duke formuar nj&euml; krater t&euml; vog&euml;l n&euml; midis. Duke u rritur ajo mund t&euml; duket si nj&euml; ulcer&euml; q&euml; nuk sh&euml;rohet.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Karcinoma e qelizave skuamoze. Kjo mund t&euml; filloj&euml; si nj&euml; e &euml;njtur e fort&euml; e vog&euml;l q&euml; nuk dhemb ose njoll&euml; e vrazhd&euml;t me luspa, zakonisht n&euml; pjes&euml;n prapme t&euml; dor&euml;s, ose t&euml; buz&euml;ve ose t&euml; veshit. Ajo ngadal&euml; b&euml;het m&euml; e madhe dhe mund t&euml; duket gati si lyeth.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Shkoni dhe vizitoni mjekun tuaj p&euml;r k&euml;shill&euml; n&euml;se v&euml;reni ndonj&euml;rin prej k&euml;tyre simptomeve.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Farmacisti juaj gjithashtu mund t&euml; jet&euml; n&euml; gjendje t&euml; ju ndihmoj&euml;. Kapja e hershme e shumic&euml;s s&euml; kancereve t&euml; l&euml;kur&euml;s &euml;sht&euml; e trajtueshme.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">Pse disa njer&euml;z marrin ngjyr&euml;n m&euml; leht&euml;, nd&euml;rsa t&euml; tjer&euml;t vet&euml;m digjen?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">P&euml;rgjigjja &euml;sht&euml; n&euml; gjenet tuaja! Kjo vet&euml; varet nga l&euml;kura me t&euml; cil&euml;n keni lindur. L&euml;kura juaj prodhon nj&euml; pigment t&euml; quajtur melanin&euml; kur ekspozohet ndaj diellit. &Euml;sht&euml; aft&euml;sia juaj p&euml;r t&euml; prodhuar melanin&euml; e cila p&euml;rcakton n&euml;se ju nxiheni leht&euml;. Njer&euml;zit me flok&euml; t&euml; &ccedil;ela kan&euml; tendenc&euml; m&euml; t&euml; vog&euml;l t&euml; prodhimit t&euml; melanin&euml;s se sa ata me flok&euml; t&euml; mbyllt&euml;. Sidoqoft&euml;, niveli i mbrojtjes t&euml; cil&euml;n e jep nxirja &euml;sht&euml; shum&euml; e kufizuar dhe me kalimin e koh&euml;s pjesa m&euml; e madhe e d&euml;mit &euml;sht&euml; b&euml;r&euml;.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">Si mund t&euml; evitoj djegien nga dielli?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">P&euml;rgjigjja e thjesht&euml; &euml;sht&euml; &ndash; rri larg nga dielli! Por, n&euml;se d&euml;shironi t&euml; k&euml;naqeni me rrezet e diellit ose n&euml;se nuk mund ta evitoni, at&euml;her&euml; k&euml;shillat n&euml; vijim mund t&euml; ndihmojn&euml;: evitoni diellin nd&euml;rmjet 11.00 PD dhe 3.00 MD gjat&euml; Majit deri n&euml; Shtator; mbani kapel&euml; dhe veshje t&euml; &ccedil;lira t&euml; cilat mbulojn&euml; l&euml;kur&euml;n tuaj; mbani kujdes shtes&euml; af&euml;r sip&euml;rfaqeve reflektuese si&ccedil; jan&euml; uji, bora dhe r&euml;ra; mbani syza t&euml; aprovuara p&euml;r diell (n&euml; UK BS 2724) dhe jeni t&euml; sigurt q&euml; jeni duke p&euml;rdorur kremra dhe losione p&euml;r mbrojtje nga dielli me SPF (Sun Protection Factor - Faktor Mbrojtjeje nga Dielli) prej s&euml; paku 15 dhe me mbrojtje nga t&euml; dy llojet e rrezatimeve UVA dhe UVB.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Pyetni farmacistin tuaj p&euml;r k&euml;shilla t&euml; m&euml;tejshme n&euml;se &euml;sht&euml; e nevojshme.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">&Ccedil;ka &euml;sht&euml; SPF dhe rangimi me yje i losioneve dhe kremrave p&euml;r mbrojtje ndaj diellit dhe si t&euml; zgjedh t&euml; duhurin?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Mbrojt&euml;sit e diellit mbrojn&euml; n&euml; dy m&euml;nyra:</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Duke reflektuar rrezet UV nga l&euml;kura.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">&bull; Duke absorbuar rrezet UV para se ato t&euml; dep&euml;rtojn&euml; n&euml; l&euml;kur&euml;.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">SPF &euml;sht&euml; shkurtes&euml; p&euml;r Faktor Mbrojt&euml;s nga Dielli (Sun Protection Factor) &ndash; sa m&euml; i lart&euml; &euml;sht&euml; numri, aq m&euml; e madhe &euml;sht&euml; mbrojtja, dhe indikon p&euml;r sa koh&euml; ju mund t&euml; q&euml;ndroni n&euml; diell pa u djegur. L&euml;kura e secilit &euml;sht&euml; e ndryshme por ju duhet t&euml; zgjidhni mbrojt&euml;s dielli me SPF prej s&euml; paku 15 dhe me mbrojtje nga t&euml; dyja rrezatimet UVA dhe UVB. Sistemi i rangimit t&euml; rrezatimit me yje p&euml;r mbrojt&euml;sit e diellit indikojn&euml; shkall&euml;n e mbrojtjes nga UVA rrezatimi. Sa m&euml; shum&euml; yje n&euml; paketim aq m&euml; e madhe &euml;sht&euml; mbrojtja. Idealisht, ju duhet t&euml; keni p&euml;r q&euml;llim t&euml; redukoni ekspozimin ndaj UVA dhe UVB barabar, n&euml; m&euml;nyr&euml; q&euml; t&euml; mos i ekspozoheni nj&euml;rit m&euml; shum&euml; se tjetrit, k&euml;shtu q&euml; &euml;sht&euml; e arsyeshme q&euml; t&euml; zgjidhet produkti i cili ofron mbrojtje superiore UVA (tre ose kat&euml;r yje) dhe rang t&euml; lart&euml; SPF.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Bleni preparat p&euml;r mbrojtje nga dielli me SPF prej s&euml; paku 15 me rangim t&euml; lart&euml; yjesh.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">Si mund t&euml; kem leverdi maksimale nga losioni p&euml;r mbrojtje nga dielli?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">L&euml;kur&euml;s suaj i duhen vet&euml;m disa minuta p&euml;r t&euml; absorbuar preparatin p&euml;r mbrojtje nga dielli k&euml;shtu q&euml; m&euml; s&euml; miri &euml;sht&euml; ta aplikoni para se t&euml; dilni n&euml; diell. Riapliko shpesh, posa&ccedil;&euml;risht mbas notit, por p&euml;rcillni instruksionet n&euml; paketim. Duhet t&euml; jeni posa&ccedil;&euml;risht t&euml; kujdessh&euml;m me regjionet e ndjeshme si&ccedil; jan&euml; hunda, thimthat, vesh&euml;t, shputat e k&euml;mb&euml;ve dhe n&euml;se flok&euml;t hollohen at&euml;her&euml; edhe maj&euml;n e kok&euml;s.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">&Ccedil;ka n&euml;se jam alergjik n&euml; disa produkte p&euml;r l&euml;kur&euml;?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Disa njer&euml;z jan&euml; alergjik&euml; n&euml; disa preparate p&euml;r mbrojtje nga dielli. N&euml;se jeni edhe ju, zgjidhni produktin i cili nuk p&euml;rmban parfum dhe hipoalergjik dhe i cili ofron mbrojtje m&euml; t&euml; lart&euml; UVA.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Pyetni farmacistin p&euml;r k&euml;shill&euml; n&euml;se jeni t&euml; brengosur p&euml;r efektin e preparatit p&euml;r mbrojtje nga dielli.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">&Ccedil;ka &euml;sht&euml; foto-mplakja?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Kur njer&euml;zit i jan&euml; ekspozuar tep&euml;r shum&euml; drit&euml;s s&euml; diellit te ata mund t&euml; zhvillohen simptomet e foto-mplakjes: nishanet; njollat (sip&euml;rfaqe ngjyr&euml; kafe n&euml; fytyr&euml; dhe an&euml;t e sip&euml;rme t&euml; duarve); l&euml;kur&euml; e vrazhd&euml;t, e l&euml;varur dhe e meshint&euml;; dhe rrudha si ato t&euml; syve.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">N&euml;se mendoni q&euml; n&euml; l&euml;kur&euml;n tuaj jan&euml; zhvilluar k&euml;to efekte, at&euml;her&euml; pyetni farmacistin ose mjekun tuaj p&euml;r k&euml;shill&euml; lidhur me prevenimin e d&euml;mtimit t&euml; m&euml;tejsh&euml;m t&euml; l&euml;kur&euml;s dhe n&euml;se ka n&euml; dispozicion trajtim t&euml; mundsh&euml;m.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">Kush &euml;sht&euml; m&euml; shum&euml; n&euml; rrezik nga d&euml;mtimi i shkaktuar nga dielli?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Njer&euml;zit me pun&euml; t&euml; fush&euml;s, ata me l&euml;kur&euml; t&euml; &ccedil;el&euml; dhe n&euml;pun&euml;sit e zyrave me l&euml;kur&euml; t&euml; zbeht&euml; t&euml; cil&euml;t rreziten intensivisht p&euml;r disa jav&euml; p&euml;r &ccedil;do vit, jan&euml; nd&euml;rmjet atyre q&euml; m&euml; s&euml; shumti i n&euml;nshtrohen rrezikut nga dielli.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">L&euml;kura e f&euml;mij&euml;ve &euml;sht&euml; m&euml; e holl&euml; dhe m&euml; e ndjeshme sesa e t&euml; rriturve k&euml;shtu q&euml; duhet pasur kujdes t&euml; shtuar p&euml;r t&euml;. Foshnjat n&euml;n mosh&euml;n 6 mujore do t&euml; duhej t&euml; mbahen larg diellit dhe bashk&euml; me k&euml;t&euml; &ndash; preparatet p&euml;r mbrojtje nga dielli zakonisht nuk rekomandohen p&euml;r ta, por ndihmojn&euml; t&euml; gjitha kapelat, veshjet e p&euml;rshtatshme dhe hijet.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">Mbrojtja e f&euml;mij&euml;ve nga dielli n&euml; mosh&euml;n e<span>&nbsp; </span>re do t&euml; reduktoj&euml; rrezikun nga kanceri i l&euml;kur&euml;s dhe foto-mplakja m&euml; von&euml; gjat&euml; jet&euml;s.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"></span></p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal">&nbsp;</p><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span class="IntenseEmphasis"><span style="font-family: Calibri; font-size: 10pt"><strong><em><font color="#4f81bd">&Ccedil;ka duhet t&euml; vendos n&euml; l&euml;kur&euml; pas ekspozimit n&euml; diell?</font></em></strong></span></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt; text-align: justify" class="MsoNormal"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">P&euml;rdor krem hidratant zbut&euml;s t&euml; pa-parfumosur. Kjo do t&euml; ndihmoj&euml; mbajtjen e l&euml;kur&euml;s t&euml; hidratuar dhe t&euml; but&euml;, por nuk do t&euml; rikthej&euml; d&euml;mtimin e b&euml;r&euml; n&euml;se e tej-ekspozoni veten.</font></span></p><font face="Times New Roman" size="3" color="#000000">  </font><p style="margin: 0cm 0cm 0pt" class="MsoFooter">&nbsp;</p><p style="margin: 0cm 0cm 0pt" class="MsoFooter">&nbsp;</p><p style="margin: 0cm 0cm 0pt" class="MsoFooter"><span style="font-family: Calibri; font-size: 10pt"><font color="#000000">P&euml;rgatiti<em>: Adnan Mustafa, MPharm</em></font></span></p></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Sun, 10 Jul 2011 21:18:38 +0000</pubDate>
		</item>
		<item>
			<title>Propilen glikoli-dermatiti alergjik kontakti</title>
			<link>/indeks/index.php/component/k2/item/185-propilen-glikoli-dermatiti-alergjik-kontakti</link>
			<guid>/indeks/index.php/component/k2/item/185-propilen-glikoli-dermatiti-alergjik-kontakti</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><!--[if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal</w:View>   <w:Zoom>0</w:Zoom>   <w:PunctuationKerning/>   <w:ValidateAgainstSchemas/>   <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false</w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>   <w:Compatibility>    <w:BreakWrappedTables/>    <w:SnapToGridInCell/>    <w:WrapTextWithPunct/>    <w:UseAsianBreakRules/>    <w:DontGrowAutofit/>   </w:Compatibility>   <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml>  <w:LatentStyles DefLockedState="false" LatentStyleCount="156">  </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style>  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} </style> <![endif]-->  <h4><span style="font-size: 10pt; font-family: Arial; font-weight: normal"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/meds/pg.jpg" width="120" height="93" hspace="6" alt="Propilen glikol" title="Propilen glikol" border="0" /><div class="mosimage_caption">Propilen glikol</div></div> Shkaktar shpesh i padetektuar i dermatitit alergjik kontakti n&euml; pacient&euml;t q&euml; p&euml;rdorin kortikosteroide topikale</span></h4>  <p><span style="font-size: 10pt; font-family: Arial">Propilen glikoli (PG) konsiderohet t&euml; jet&euml; p&euml;rb&euml;r&euml;s i gjith&euml;pranish&euml;m i formulacioneve i p&euml;rdorur n&euml; produktet p&euml;r p&euml;rkujdes personal dhe preparate farmaceutike.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Ai &euml;sht&euml; komponim organik q&euml; gjendet r&euml;ndom n&euml; kortikosteroide topikale (KT).</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Reaksionet l&euml;kurore n&euml; PG n&euml; t&euml; shumt&euml;n jan&euml; irrituese, por dermatiti alergjik kontakti n&euml; PG &euml;sht&euml; i dokumentuar mir&euml;.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Kosenzitizimi n&euml; PG dhe KT mund t&euml; shfaqet, duke b&euml;r&euml; sfiduese zgjedhjen e kortikosteroideve topikale n&euml; pacient&euml;t alergjik n&euml; PG.</span><span style="font-size: 10pt; font-family: Arial"> </span></p>  </div><div class="K2FeedFullText"><!--[if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal</w:View>   <w:Zoom>0</w:Zoom>   <w:PunctuationKerning/>   <w:ValidateAgainstSchemas/>   <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false</w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>   <w:Compatibility>    <w:BreakWrappedTables/>    <w:SnapToGridInCell/>    <w:WrapTextWithPunct/>    <w:UseAsianBreakRules/>    <w:DontGrowAutofit/>   </w:Compatibility>   <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml>  <w:LatentStyles DefLockedState="false" LatentStyleCount="156">  </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style>  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} </style> <![endif]-->  <p><span style="font-size: 10pt; font-family: Arial">Propilen glikoli (PG) &euml;sht&euml; l&euml;ng pa ngjyr&euml;, viskoz, gati pa arom&euml; q&euml; p&euml;rdoret si produkt intermediar p&euml;r sintez&euml;n e kimikateve tjera.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Ai &euml;sht&euml; ekscipient multifunksional q&euml; p&euml;rdoret n&euml; shum&euml; produkte si solvent, vehikulum, humektant ose emulzifikues.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Vehikulumet p&euml;r preparatet kortikosteroidale r&euml;ndom p&euml;rfshijn&euml; PG p&euml;r thellimin e penetrimit n&euml; stratum corneum.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Si shtes&euml; e steroideve topikale. PG gjitashtu mund t&euml; gjendet n&euml; preparatet tjera farmakologjike topikale, p&euml;rfshir&euml; antibiotik&euml;t, antimikotik&euml;t, benzoil peroksid dhe emolient&euml;t.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Reaksionet l&euml;kurore n&euml; PG jan&euml; t&euml; njohura q&euml; nga viti 1952.</span><span style="font-size: 10pt; font-family: Arial"> </span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">P&euml;r ma shum&euml; klikoni (n&euml;se jeni t&euml; regjistruar n&euml; Medscape):</span><span style="font-size: 10pt; font-family: Arial"> <span><a href="http://www.medscape.com/viewarticle/742812?src=rss">http://www.medscape.com/viewarticle/742812?src=rss</a></span> </span></p>  </div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Fri, 08 Jul 2011 22:32:49 +0000</pubDate>
		</item>
		<item>
			<title>Topiramat-çarje e buzës dhe qiellzës</title>
			<link>/indeks/index.php/component/k2/item/184-topiramat-çarje-e-buzës-dhe-qiellzës</link>
			<guid>/indeks/index.php/component/k2/item/184-topiramat-çarje-e-buzës-dhe-qiellzës</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><p><span style="layout-grid-mode: line; font-family: Arial; font-size: 10pt"><font color="#000000"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/meds/topamax1.jpg" width="107" height="198" hspace="6" alt="topiramat" title="topiramat" border="0" /><div class="mosimage_caption">topiramat</div></div> FDA e ShBA ka njoftuar profesionist&euml;t sh&euml;ndet&euml;sor dhe pacient&euml;t p&euml;r rritje&nbsp;rreziku nga zhvillimi i &ccedil;arjes s&euml; buz&euml;s dhe/ose &ccedil;arjes s&euml; qiellz&euml;s n&euml; foshnjat e lindura nga grat&euml; e&nbsp;trajtuara me topiramat gjat&euml; shtatzanis&euml;.</font></span></p></div><div class="K2FeedFullText"><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Topiramati &euml;sht&euml; bar antikonvulzant q&euml; &euml;sht&euml; aprovuar p&euml;r p&euml;rdorim si i vet&euml;m ose me barna tjera p&euml;r t&euml; trajtuar pacient&euml;t me epilepsi t&euml; cil&euml;t kan&euml; disa tipe t&euml; ve&ccedil;anta t&euml; konvulsioneve.</span></font><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Topiramati gjithashtu &euml;sh&euml;t i parovuar p&euml;r p&euml;rdorim p&euml;r t&euml; prevenuar kok&euml;dhimbjet migrenike. FDA e ShBA shpjegon q&euml; t&euml; dh&euml;nat nga Regjistri i Shtatzanis&euml; i North American Antiepileptic Drug (NAAED), nj&euml; grup q&euml; mbledh informacione lidhur me rezultatet e foshnjave t&euml; porsalindura nga grat&euml; e trajtuara me barna antiepileptike gjat&euml; shtatzanis&euml;, indikojn&euml; rritje t&euml; rrezikut nga &ccedil;arjet orale n&euml; foshnjat e ekspozuara n&euml; monoterapi topiramati gjat&euml; trimestrit t&euml; par&euml; t&euml; shtatzanis&euml;.</span></font><font color="#000000"><span style="font-family: Arial; font-size: 10pt">P&euml;r shkak t&euml; rrezikut t&euml; rritur p&euml;r &ccedil;arje orale, topiramati &euml;sht&euml; vendosur n&euml; Kategorin&euml; e Shtatzanis&euml; D, q&euml; do t&euml; thot&euml; q&euml; ekziston evidenc&euml; pozitive e rrezikut fetal e bazuar n&euml; t&euml; dh&euml;nat humane, por leverdia e barit n&euml; grat&euml; shtatzana mund t&euml; tejkaloj&euml; rrezikun n&euml; raste t&euml; caktuara. Udh&euml;zimi p&euml;r p&euml;rdorimin e barit dhe informacioni p&euml;r p&euml;rshkrimin e topiramatit do t&euml; azhurohen me informacione t&euml; reja.</span></font><font color="#000000"><span style="font-family: Arial; font-size: 10pt">FDA e ShBA k&euml;shillon q&euml; leverdit&euml; dhe rreziqet e topiramatit do duhej t&euml; maten me kujdes kur p&euml;rshkruhet ky bar te grat&euml; e mosh&euml;s fertile, posa&ccedil;&euml;risht p&euml;r gjendjet q&euml; nuk jan&euml; zakonisht t&euml; nd&euml;rlidhura me d&euml;mtim permanent ose vdekje. Barnat alternative t&euml; cilat kan&euml; rrezik ma t&euml; ult&euml; t&euml; &ccedil;arjes orale dhe rezultate tjera t&euml; lindjes do duhej t&euml; konsiderohen p&euml;r k&euml;ta pacient&euml;. N&euml;se &euml;sht&euml; marr&euml; vendim p&euml;r p&euml;rshkrim t&euml; topiramatit te grat&euml; e mosh&euml;s fertile, profesionist&euml;t sh&euml;ndet&euml;sor do duhej t&euml; rekomandojn&euml; kontracepsion efektiv p&euml;r grat&euml; t&euml; cilat nuk planifikojn&euml; shtatzani, duke mbajtur n&euml; mend potencialin p&euml;r ulje t&euml; ekspozimit hormonal n&euml; efikasitetin kontraceptiv kur p&euml;rdoren mjetet e kontrollit t&euml; lindjes q&euml; p&euml;rmbajn&euml; estrogjen bashk&euml; me topiramat.</span></font> <p><span style="layout-grid-mode: line; font-family: Arial; font-size: 10pt"><font color="#000000">&Ccedil;arjet orale shfaqen n&euml; trimestrin e par&euml; t&euml; shtatzanis&euml; para se shum&euml; gra t&euml; marrin vesh se jan&euml; shtatzana.</font></span></p><p><span style="layout-grid-mode: line; font-family: Arial; font-size: 10pt"><font color="#000000">Burimi: WHO Newsletter, No.2, 2011</font></span></p></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Tue, 10 May 2011 00:33:18 +0000</pubDate>
		</item>
		<item>
			<title>Buflomedil-tërhiqet nga tregu</title>
			<link>/indeks/index.php/component/k2/item/182-buflomedil-tërhiqet-nga-tregu</link>
			<guid>/indeks/index.php/component/k2/item/182-buflomedil-tërhiqet-nga-tregu</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><!--[if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal</w:View>   <w:Zoom>0</w:Zoom>   <w:PunctuationKerning/>   <w:ValidateAgainstSchemas/>   <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false</w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>   <w:Compatibility>    <w:BreakWrappedTables/>    <w:SnapToGridInCell/>    <w:WrapTextWithPunct/>    <w:UseAsianBreakRules/>    <w:DontGrowAutofit/>   </w:Compatibility>   <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml>  <w:LatentStyles DefLockedState="false" LatentStyleCount="156">  </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style>  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} </style> <![endif]--><span style="font-size: 10pt; font-family: Arial"><img src="/images/stories/meds/loftyl.jpg" width="120" height="84" style="float: left;" hspace="6" alt="buflomedil" title="buflomedil" border="0" /> Autorizimi p&euml;r marketing &euml;sht&euml; suspenduar n&euml; Franc&euml;.</span><span style="font-size: 10pt; font-family: Arial"> </span><span style="font-size: 10pt; font-family: Arial">Agjencia Franceze p&euml;r Siguri t&euml; Produkteve Sh&euml;ndet&euml;sore (Afssaps) ka vendosur m&euml; 11 shkurt 2011, p&euml;r suspendimin e autorizimit p&euml;r marketing t&euml; produkteve q&euml; p&euml;rmbajn&euml; buflomedil.</span></div><div class="K2FeedFullText"><!--[if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal</w:View>   <w:Zoom>0</w:Zoom>   <w:PunctuationKerning/>   <w:ValidateAgainstSchemas/>   <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false</w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>   <w:Compatibility>    <w:BreakWrappedTables/>    <w:SnapToGridInCell/>    <w:WrapTextWithPunct/>    <w:UseAsianBreakRules/>    <w:DontGrowAutofit/>   </w:Compatibility>   <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml>  <w:LatentStyles DefLockedState="false" LatentStyleCount="156">  </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style>  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Table Normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:"Times New Roman"; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} </style> <![endif]-->  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">T&euml; gjitha serit&euml; e produkteve q&euml; p&euml;rmbajn&euml; buflomedil jan&euml; revokuar n&euml; Franc&euml; m&euml; 17 shkurt 2011.</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Aksioni &euml;sht&euml; nd&euml;rmarr&euml; pas lajm&euml;rimeve t&euml; ngjarjeve serioze nervore (konvulsione, miklonusi dhe statusi epileptik) dhe kardiake (tahikardia, hipotensioni, &ccedil;rregullimet e e ritmit ventrikular dhe arresti kardiak) posa&ccedil;&euml;risht n&euml; tejdozimin aksidental ose t&euml; vullnetsh&euml;m.</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">(Shikoni WHO Newsletter No. 1, 2007 p&euml;r vendimin e Afssaps p&euml;r t&euml; t&euml;rhequr buflomedilin 300 mg tabletat nga tregu p&euml;r shkak t&euml; rrezikut nga suicidi.)</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">&nbsp;</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Referenca:</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Sp&eacute;cialit&eacute;s &agrave; base de Buflom&eacute;dil - Retrait de produits, Afssaps, 17 Shkurt 2011</span></p>  <p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">(<span><a href="http://www.afssaps.fr/"><span>www.afssaps.fr</span></a>)</span></span></p>  </div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Sat, 07 May 2011 02:33:17 +0000</pubDate>
		</item>
		<item>
			<title>Dozimi i paracetamolit-BNFC</title>
			<link>/indeks/index.php/component/k2/item/181-dozimi-i-paracetamolit-bnfc</link>
			<guid>/indeks/index.php/component/k2/item/181-dozimi-i-paracetamolit-bnfc</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/meds/paracet.jpg" width="120" height="121" hspace="6" alt="paracetamol" title="paracetamol" border="0" /><div class="mosimage_caption">paracetamol</div></div> P&euml;rdorimi i lejuar:</span></strong><span style="font-family: Arial; font-size: 10pt"> </span><span style="font-family: Arial; font-size: 10pt">Nuk &euml;sht&euml; i lejuar p&euml;rdorimi oral n&euml; f&euml;mij&euml;t n&euml;n mosh&euml;n 2 vje&ccedil;are; dozat p&euml;r simptoma t&euml; r&euml;nda nuk jan&euml; t&euml; lejuara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Indikacionet dhe doza&nbsp;</font></span></strong><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></strong></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">Dhembja; pireksia dhe parehatia</span></strong></font><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></strong></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">&bull;P&euml;rmes goj&euml;s</span></strong></font></p><p><font color="#000000"><strong></strong></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Neonat&euml;t 28-32 jav&euml; t&euml; mosh&euml;s postmenstruale: 20 mg/kg si doz&euml; nj&euml;sore pastaj 10-15 mg/kg &ccedil;do 8-12 or&euml; sipas nevoj&euml;s; max. 30 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</font></span></p></div><div class="K2FeedFullText"><p><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Indikacionet dhe doza&nbsp;</font></span></strong><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></strong></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">Dhembja; pireksia dhe parehatia</span></strong></font><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></strong></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">&bull;P&euml;rmes goj&euml;s</span></strong></font></p><p><font color="#000000"></font><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Neonat&euml;t 28-32 jav&euml; t&euml; mosh&euml;s postmenstruale: 20 mg/kg si doz&euml; nj&euml;sore pastaj 10-15 mg/kg &ccedil;do 8-12 or&euml; sipas nevoj&euml;s; max. 30 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Neonat&euml;t mbi 32 jav&euml; t&euml; mosh&euml;s postmenstruale: 20 mg/kg si doz&euml; nj&euml;sore pastaj 10-15 mg/kg &ccedil;do 6-8 or&euml; sipas nevoj&euml;s; max. 60 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-3 muajsh 30-60 mg &ccedil;do 8 or&euml; sipas nevoj&euml;s</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 3-12 muajsh 60-120 mg &ccedil;do 4-6 or&euml; (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-6 vje&ccedil; 120-250 mg &ccedil;do 4-6 or&euml; (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 6-12 vje&ccedil; 250-500 mg &ccedil;do 4-6 or&euml; (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 12-18 vje&ccedil; 500 mg &ccedil;do 4-6 or&euml;</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">&bull;P&euml;rmes rektumit</span></strong></font> </p><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Neonat&euml;t 28-32 jav&euml; t&euml; mosh&euml;s postmenstruale: 20 mg/kg si doz&euml; nj&euml;sore pastaj 15 mg/kg &ccedil;do 12 or&euml; sipas nevoj&euml;s; max. 30 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Neonat&euml;t mbi 32 jav&euml; t&euml; mosh&euml;s postmenstruale: 30 mg/kg si doz&euml; nj&euml;sore pastaj 20 mg/kg &ccedil;do 8 or&euml; sipas nevoj&euml;s; max. 60 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-3 muajsh 30-60 mg &ccedil;do 8 or&euml; sipas nevoj&euml;s</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 3-12 muajsh 60-125 mg &ccedil;do 4-6 or&euml; sipas nevoj&euml;s (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-5 vje&ccedil; 125-250 mg &ccedil;do 4-6 or&euml; sipas nevoj&euml;s (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 5-12 vje&ccedil; 250-500 mg &ccedil;do 4-6 or&euml; sipas nevoj&euml;s (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 12-18 vje&ccedil; 500 mg &ccedil;do 4-6 or&euml;</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span> </p><p style="margin: 0cm 0cm 0pt" class="MsoNormal">&nbsp;</p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">&bull;Me infuzion intravenoz gjat&euml; 15 minutave</span></strong></font> <p style="margin: 0cm 0cm 0pt" class="MsoNormal">&nbsp;</p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">Neonat&euml;t 7.5 mg/kg &ccedil;do 4-6 or&euml;; max. 30 mg/kg n&euml; dit&euml;</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t me pesh&euml; trupore n&euml;n 10 kg 7.5 mg/kg &ccedil;do 4-6 or&euml;; max. 30 mg/kg n&euml; dit&euml;</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t me pesh&euml; trupore 10-50 kg 15 mg/kg &ccedil;do 4-6 or&euml;; max. 60 mg/kg n&euml; dit&euml;</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t me pesh&euml; trupore mbi 50 kg 1 g &ccedil;do 4-6 or&euml;; max. 4 g n&euml; dit&euml;</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span> </p><p style="margin: 0cm 0cm 0pt" class="MsoNormal">&nbsp;</p><p><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">Dhembja e fort&euml;; </font></span></strong><strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">pireksia e r&euml;nd&euml;</font></span></strong><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">&bull;P&euml;rmes goj&euml;s</span></strong></font> </p><p style="margin: 0cm 0cm 0pt" class="MsoNormal"><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-3 muajsh 20-30 mg/kg si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 60 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 3-12 muajsh 20-30 mg/kg si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 90 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-6 vje&ccedil; 20-30 mg/kg si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 90 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 6-12 vje&ccedil; 20-30 mg/kg (max. 1 g) si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 90 mg/kg (max. 4 g) n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 12-18 vje&ccedil; 1 g &ccedil;do 4-6 or&euml; (max. 4 doza n&euml; 24 or&euml;)</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><strong><span style="font-family: Arial; font-size: 10pt">&bull;P&euml;rmes rektumit</span></strong></font></p><p><font color="#000000"></font><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-3 muajsh 30 mg/kg si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 60 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 3-12 muajsh 30-40 mg/kg si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 90 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 1-6 vje&ccedil; 30-40 mg/kg si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 90 mg/kg n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><font color="#000000"><span style="font-family: Arial; font-size: 10pt">F&euml;mij&euml;t 6-12 vje&ccedil; 30-40 mg/kg (max. 1 g) si doz&euml; nj&euml;sore pastaj 15-20 mg/kg &ccedil;do 6-8 or&euml;; max. 90 mg/kg (max. 4 g) n&euml; dit&euml; n&euml; doza t&euml; ndara</span></font><span style="font-family: Arial; font-size: 10pt"><font color="#000000">&nbsp;</font></span></p><p><span style="font-family: Arial; font-size: 10pt"><font color="#000000">F&euml;mij&euml;t 12-18 vje&ccedil; 1 g &ccedil;do 4-6 or&euml; (max. 4 doza n&euml; 24 or&euml;)</font></span></p></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Sat, 25 Sep 2010 00:39:49 +0000</pubDate>
		</item>
		<item>
			<title>Tramadol-ndryshim etikete</title>
			<link>/indeks/index.php/component/k2/item/179-tramadol-ndryshim-etikete</link>
			<guid>/indeks/index.php/component/k2/item/179-tramadol-ndryshim-etikete</guid>
			<description><![CDATA[<div class="K2FeedIntroText"><span style="line-height: 115%; font-family: &#39;Calibri&#39;,&#39;sans-serif&#39;; font-size: 11pt"><font color="#000000"><div class="mosimage"  style=" float: left;" align="center"><img src="/images/stories/meds/ultram.jpg" width="120" height="155" hspace="6" alt="tramadol" title="tramadol" border="0" /><div class="mosimage_caption">tramadol</div></div> ShBA. 25 Maj 2010. Ortho-McNeil-Janssen dhe FDA ka njoftuar profesionist&euml;t sh&euml;ndet&euml;sor p&euml;r ndryshimet n&euml; seksionin&nbsp;e Paralajm&euml;rimeve lidhur me informacionet e p&euml;rshkrimit p&euml;r tramadol, analgjetik opioid me veprim qendror i indikuar p&euml;r menaxhim t&euml; dhembjes kronike mesatare deri mesatarisht t&euml; r&euml;nd&euml;.</font></span></div><div class="K2FeedFullText"><p><span style="line-height: 115%; font-family: &#39;Calibri&#39;,&#39;sans-serif&#39;; font-size: 11pt"><font color="#000000">Informacioni i sforcuar i Paralajm&euml;rimeve thekson rrezikun e suicidit p&euml;r pacient&euml;t t&euml; cil&euml;t jan&euml; t&euml; prirur p&euml;r varshm&euml;ri, q&euml; marrin trankilizer&euml; ose barna antidepresive dhe gjithashtu paralajm&euml;ron p&euml;r rrezik nga tejdozimi. Vdekjet <span>&nbsp;</span>e nd&euml;rlidhura me tramadol jan&euml; paraqitur n&euml; pacient&euml;t me histori paraprake t&euml; &ccedil;rregullimeve emocionale ose ideve ose tentimeve suicidale, sikurse edhe historive t&euml; keqp&euml;rdorimit t&euml; tankilizer&euml;ve, alkoolit dhe barnave tjera q&euml; veprojn&euml; n&euml; SNQ. Tramadol mund t&euml; pritet t&euml; ket&euml; efekt aditiv kur p&euml;rdoret bashk&euml; me alkool, opioide tjera ose barna t&euml; kontrolluara q&euml; shkaktojn&euml; depresion t&euml; sistemit nervor qendror. Konsekuencat potencialisht serioze t&euml; tejdozimit me tramadol jan&euml; depresioni i sistemit nervor qendror, depresioni respirator dhe vdekja. Tramadol ka aktivitet mu-opioid agonist, mund t&euml; abuzohet dhe mund t&euml; jet&euml; subjekt i ndjekjes kriminale. </font></span></p><p><span style="line-height: 115%; font-family: &#39;Calibri&#39;,&#39;sans-serif&#39;; font-size: 11pt"><font color="#000000">Burimi:<a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213264.htm"> MedWatch</a></font></span></p></div>]]></description>
			<author>webmaster@pharmaks.com (Adnan Mustafa)</author>
			<category>Farmakovigjilencë</category>
			<pubDate>Tue, 25 May 2010 19:06:36 +0000</pubDate>
		</item>
	</channel>
</rss>
